Miles' Gamimune-N
Executive Summary
Biological Products Unit files PLA for I.V. immunoglobulin (IVIG) for the treatment of AIDS in children with CD4+ cell counts of at least 200, firm announces Nov. 5. Results of a pivotal clinical trial of 376 symptomatic HIV-positive children treated with Gamimune-N, conducted by the National Institute of Child Health and Human Development (NICHD), were published in July ("The Pink Sheet" Aug. 3, T&G-11).